Early Noninvasive Ventilation May Not Be Better for Patients With Acute Respiratory Failure
the ONA take:
Among immunocompromised patients admitted to intensive care units (ICUs) with hypoxemic acute respiratory failure, early noninvasive ventilation did not reduce 28-day mortality compared with oxygen therapy alone, according to a new study published online ahead of print in JAMA.
Although noninvasive ventilation has been recommended to decrease mortality among immunocompromised patients with hypoxemic acute respiratory failure, its effectiveness has remained unclear.
Therefore, researchers sought to evaluate whether early noninvasive ventilation improved survival in these patients.
For the multicenter trial, researchers enrolled 374 critically ill immunocompromised patients at 28 ICUs in France and Belgium.
Of those, nearly 85% were receiving treatment for hematologic malignancies and solid tumors. Participants were randomly assigned to receive early noninvasive ventilation or oxygen therapy alone.
Results showed that at 28 days after randomization, 46 deaths had occurred in the noninvasive ventilation group compared with 50 in the oxygen group (P=0.47). In addition, oxygenation failure occurred in 73 patients and 82 patients, respectively (P=0.20).
Researchers found no significant differences in ICU-acquired infections, duration of mechanical ventilation, or lengths of ICU or hospital stays between the two treatment arms.
The authors note that the study power was limited and this may affect the applicability of the findings.
Early noninvasive ventilation did not reduce 28-day mortality compared with oxygen therapy alone.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|